Adjuvant Chemotherapy for Patients with Soft Tissue Sarcoma

Ozaki Toshifumi

Sugihara Shinsuke

Hamada Masanori

Nakagawa Yukou

Inoue Hajime

Hiroshima Journal of Medical Sciences

[PISSN] 0018-2052

[EISSN] 2433-7668

[NCID] AA00664312

Forty patients with soft tissue sarcoma (Enneking's stage I and II) were treated in our department between 1965 and 1992. We administered VACA regimen (composed of vincristine, actinomycin-D, cyclophosphamide, and doxorubicin) to 14 of 40 patients. Among 40 patients, the 5-year survival rate was 56% in 14 patients with chemotherapy and 39% in 26 without chemotherapy (p<0.02). In 32 patients of Stage II, the 5-year survival rate was 40% in 11 patients with chemotherapy and 31 % without chemotherapy (p<0.05). The improvement of the survival rate was due to delay in the development of lung metastases (chemotherapy group: 21.2 months after first visit, non-chemotherapy group: 9.4 months) and prolongation of the survival period after metastases (chemotherapy group: 26 months, non-chemotherapy group: 7.4 months).

Soft tissue sarcoma

Chemotherapy

Survival

医学 [ 490 ]

英語

Hiroshima University Medical Press

[ISSN] 0018-2052

[NCID] AA00664312